123 related articles for article (PubMed ID: 31708508)
1. [Responsiveness of well-differentiated PanNET G3 to platinum-based chemotherapy: a case report].
Kojima E; Kuba H; Matsumura M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(11):952-959. PubMed ID: 31708508
[TBL] [Abstract][Full Text] [Related]
2. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups.
Tanaka H; Hijioka S; Hosoda W; Ueno M; Kobayashi N; Ikeda M; Ito T; Kodama Y; Morizane C; Notohara K; Taguchi H; Kitano M; Komoto I; Tsuji A; Hashigo S; Kanno A; Miyabe K; Takagi T; Ishii H; Kojima Y; Yoshitomi H; Yanagimoto H; Furuse J; Mizuno N
Pancreatology; 2020 Oct; 20(7):1421-1427. PubMed ID: 32891532
[TBL] [Abstract][Full Text] [Related]
4. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
5. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
[TBL] [Abstract][Full Text] [Related]
7. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis.
Kaslow SR; Vitiello GA; Prendergast K; Hani L; Cohen SM; Wolfgang C; Berman RS; Lee AY; Correa-Gallego C
Ann Surg Oncol; 2022 Jun; 29(6):3522-3531. PubMed ID: 35246811
[TBL] [Abstract][Full Text] [Related]
8. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Pellat A; Dreyer C; Couffignal C; Walter T; Lombard-Bohas C; Niccoli P; Seitz JF; Hentic O; André T; Coriat R; Faivre S; Zappa M; Ruszniewski P; Pote N; Couvelard A; Raymond E
Neuroendocrinology; 2018; 107(1):24-31. PubMed ID: 29518779
[TBL] [Abstract][Full Text] [Related]
13. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
[TBL] [Abstract][Full Text] [Related]
14. Current Chemotherapy Use in Neuroendocrine Tumors.
Chan DL; Singh S
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):603-614. PubMed ID: 30098718
[TBL] [Abstract][Full Text] [Related]
15. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.
Guilmette JM; Nosé V
Adv Anat Pathol; 2019 Jan; 26(1):13-30. PubMed ID: 29912000
[TBL] [Abstract][Full Text] [Related]
16. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
18. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.
Sonbol MB; Halfdanarson TR
Curr Treat Options Oncol; 2019 Aug; 20(9):74. PubMed ID: 31428952
[TBL] [Abstract][Full Text] [Related]
19. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
[TBL] [Abstract][Full Text] [Related]
20. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
Singhi AD; Klimstra DS
Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
